Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (484)	10/20/2006 11:42:59 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

Additional data is expected to be presented on three cohorts of 20 subjects each at dose levels up to 10(13) particles (DRP)/mL of joint fluid at the American College of Rheumatology (ACR) meeting in November 2006. (go the the very bottom of this page) targen.com I found a poster #184 that goes along with presentation #925 at the meeting. rheumatology.org Maybe we will see a press release about that time. I don't have a feel for how Tgen is going to be dribbling out clinical data over the next year, but this first meeting is Nov 10th-15th. ASGT I think is usually in June, and that is probably the big one to watch for. I listened to the BIO presentation--Parker mentioned something about the difficulty in separating placebo effect. There are three different doses in this study, so perhaps some data will surface at the meeting in November which will look good against placebo. Good luck all! (no position, just hanging out in the cheering section here)